Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Eying Phase 3 after positive Phase 2 TD-9855 results
September 2018
SHARING OPTIONS:

DUBLIN—August saw news from Theravance Biopharma Inc. of positive four-week results from its Phase 2 clinical trial of TD-9855 in patients with symptomatic neurogenic orthostatic hypotension (nOH). Patients saw durable improvements in their disease symptom severity after four weeks as measured by the Orthostatic Hypotension Symptom Assessment Question #1, with those in the extension phase of the study demonstrating a mean symptom improvement of 2.4 points at the four-week mark. TD-9855 also led to increased systolic blood pressure, with clinically meaningful increases in standing systolic blood pressure. No drug-related serious adverse events were reported, and the drug was generally well tolerated. Theravance reported that it has completed its talks with the FDA with regards to a pivotal Phase 3 registrational program for TD-9855 and intends to kick off the program late this year or in early 2019.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.